Can Roche Find Rare Success In Alzheimer's?
Roche is about to release phase 2 data that could redefine its opportunity in this extremely hard-to-treat disease
Tuesday’s Top Biotech Stories: Johnson & Johnson, Roche, Novartis, Google
Johnson & Johnson, Roche, Novartis, Google are the top stocks to watch in health care this Tuesday morning.
Up 23%: Time to Buy Exelixis?
A great day today, but is it time to buy?
Why Exelixis Inc. Stock Soared
Exelixis shares shoot to the moon after the company delivers positive phase 3 data on its advanced melanoma combination therapy. See what this news means for investors.
Exelixis Sees Success in Melanoma Treatment With Drug Combination
Partnered with Roche-Genentech, Exelixis should be able to charge more than GlaxoSmithKline for its Melanoma treatment.
Is Becoming France the Answer to Medicare's Biggest Problem?
France has found an interesting way to save money on health care expenses. Read below for more.
3 Stocks Near 52-Week Highs Worth Selling
Are these three stocks sells or belles? You be the judge!
Should Puma Biotechnology Stock Be in Your Portfolio?
Shares of Puma Biotechnology have plummeted this year after being one of the strongest performers a year ago. Here's why this beaten down biotech belongs in your portfolio.
Time to Buy Vertex Pharmaceuticals Inc?
Vertex's cystic fibrosis franchise is just getting started.
Roche Holding Ltd Is Betting Billions on This New Blockbuster
Roche's move to pay as much as $2 billion for Seragon is a major vote of confidence for an unproven therapy approach